Back to top
more

Maravai LifeSciences (MRVI)

(Real Time Quote from BATS)

$2.12 USD

2.12
1,620,648

-0.22 (-9.40%)

Updated Aug 6, 2025 02:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Earnings Preview: Vapotherm (VAPO) Q4 Earnings Expected to Decline

by Zacks Equity Research

Vapotherm (VAPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Earnings Preview: Maravai LifeSciences Holdings, Inc. (MRVI) Q4 Earnings Expected to Decline

by Zacks Equity Research

Maravai LifeSciences Holdings, Inc. (MRVI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Maravai LifeSciences Holdings, Inc. (MRVI) Q3 Earnings Beat Estimates

by Zacks Equity Research

Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 15.63% and 1.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

LeMaitre Vascular (LMAT) Misses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

LeMaitre (LMAT) delivered earnings and revenue surprises of -10.71% and 2.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Do Options Traders Know Something About Maravai LifeSciences (MRVI) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Maravai LifeSciences (MRVI) stock based on the movements in the options market lately.

Zacks Equity Research

Maravai LifeSciences Holdings, Inc. (MRVI) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 20% and 3.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Owens & Minor (OMI) Q2 Earnings Meet Estimates

by Zacks Equity Research

Owens & Minor (OMI) delivered earnings and revenue surprises of 0% and 3.31%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Perrigo (PRGO) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Maravai LifeSciences Holdings, Inc. (MRVI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Maravai LifeSciences Holdings, Inc. (MRVI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Zacks Value Investor Highlights: Merck, Maravai LifeSciences, Sensus Healthcare, PetIQ and AbbVie

by Zacks Equity Research

Merck, Maravai LifeSciences, Sensus Healthcare, PetIQ and AbbVie have been highlighted in this Value Investor article.

Tracey Ryniec headshot

5 Cheap Healthcare Stocks in 2022

by Tracey Ryniec

Looking for value stocks? Healthcare has been ignored over the last year.

Zacks Equity Research

Implied Volatility Surging for Maravai LifeSciences (MRVI) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Maravai LifeSciences (MRVI) stock based on the movements in the options market lately.

Zacks Equity Research

Maravai LifeSciences Holdings, Inc. (MRVI) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 25.58% and 6.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Philips' (PHG) Q1 Earnings Down Y/Y on Supply Chain Constraints

by Zacks Equity Research

Koninklijke Philips' (PHG) Q1 top- and bottom-line results reflect negative impact of supply chain constraints and consequences of the Respironics field action.

Zacks Equity Research

Wall Street Analysts See a 38% Upside in Maravai LifeSciences Holdings, Inc. (MRVI): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 38.1% upside potential for Maravai LifeSciences Holdings, Inc. (MRVI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Zacks.com featured highlights include Meridian Bioscience, Innoviva, Horace Mann Educators and Maravai LifeSciences

by Zacks Equity Research

Meridian Bioscience, Innoviva, Horace Mann Educators and Maravai LifeSciences are included in this blog.

Nilanjan Banerjee headshot

Sail Through the Choppy Market With These 4 Low-Beta Stocks

by Nilanjan Banerjee

It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Meridian (VIVO), Innoviva (INVA), Horace (HMN) and Maravai LifeSciences (MRVI) are well poised to gain.

Zacks Equity Research

Can Maravai LifeSciences Holdings, Inc. (MRVI) Run Higher on Rising Earnings Estimates?

by Zacks Equity Research

Maravai LifeSciences Holdings, Inc. (MRVI) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

Can Maravai LifeSciences Holdings, Inc. (MRVI) Climb 56% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 55.8% upside potential for Maravai LifeSciences Holdings, Inc. (MRVI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Maravai LifeSciences Holdings, Inc. (MRVI) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 18.42% and 10.81%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Veru Inc. (VERU) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Veru Inc. (VERU) delivered earnings and revenue surprises of 27.27% and 17.99%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is Maravai LifeSciences Holdings, Inc. (MRVI) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Maravai LifeSciences Holdings, Inc. (MRVI) and Repligen (RGEN) have performed compared to their sector so far this year.

Debanjana Dey headshot

3 Beaten-Down Medical Product Stocks to Buy on a Turnaround in 2022

by Debanjana Dey

Here are some medical product stocks from the MedTech sector - Quidel (QDEL), Cerus (CERS) and NextGen Healthcare (NXGN) - which might be witnessing a turnaround in 2022 and be solid investment options.

Zacks Equity Research

Philips (PHG) to Buy Vesper Medical, Expand Vascular Portfolio

by Zacks Equity Research

Philips (PHG) is set to acquire Vesper Medical to strengthen its vascular devices portfolio and customer base.

Zacks Equity Research

Is LabCorp (LH) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how LabCorp (LH) and Maravai LifeSciences Holdings, Inc. (MRVI) have performed compared to their sector so far this year.